人干扰素阴道泡腾片联合匹多莫德治疗宫颈HPV感染的临床效果

目的 探讨人干扰素a2b阴道泡腾片联合匹多莫德口服液治疗宫颈持续性高危型人乳头瘤病毒(human papilloma virus, HPV)感染的临床效果。方法 选取2019-01至2020-12经解放军总医院第三医学中心妇产科确诊为宫颈持续性高危型HPV感染患者211例，依据治疗方案分为两组，联合治疗组109例，给予人干扰素a2b阴道泡腾片联合匹多莫德口服液治疗，对照组102例，给予人干扰素a2b阴道泡腾片单药治疗，观察两组治疗后6、12个月宫颈高危HPV转归情况。结果 治疗后6个月联合治疗组HPV有效率(全部转阴率)为51.38%(56/109),明显高于对照组HPV有效率23.53%(24/102),差异有统计学意义(P<0.05);治疗后12个月联合治疗组HPV有效率为73.39%(80/109),对照组HPV有效率为42.16%(43/102),差异有统计学意义(P<0.05)。进一步分析两组未转阴HPV分型，治疗后12个月，联合治疗组HPV16/18、HPV52和HPV58转阴例数均多于对照组。结论 人干扰素a2b阴道泡腾片联合匹多莫德口服液可提高宫颈高危型HP...

Clinical efficacy of human interferon vaginal effervescent tablets combined with pidotimod in treatment of cervical HPV infection

Objective To investigate the clinical efficacy of human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid in the treatment of persistent cervical high-risk type human papilloma virus (HPV).Methods A total of 211 cases with persistent cervical high-risk type HPV infection diagnosed in the Third Medical Center of PLA General Hospital were collected from January 2019 to December 2020, and they were randomly divided into two groups according to treatment options. The experimental group of 109 cases were treated with human interferon a2b vaginal effervescent tablets combined with pidotimod oral liquid, while the control group of 102 cases were treated with human interferon a2b vaginal effervescent tablets as single-agent therapy. The outcomes of cervical high-risk HPV at 6 months and 12 months after treatment were compared between the two groups.Results The effective rate (all negative conversion rate) of HPV was 51.38% (56/109) in the experimental group and 23.53% (24/102) in the control group after 6 months’ treatment, and there was a significant difference between the two groups (P<0.05).The effective rate of HPV was 73.39% (80/109) in the experimental group and 42.16% (43/102) in the control group after 12 months’ treatment, and there was a significant difference between the two groups (P<0.05). Further analysis of HPV typing remaining positive in the experimental group and the control group was conducted, and the effective rate of the top three types (HPV16/18, HPV52 and HPV58) after treatment in the experimental group was better than that in the control group.Conclusion Human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid can effectively improve the negative conversion rate of cervical high-risk type HPV, and more effective for removal of cervical HPV16/18 infection, which provides a reference for clinical treatment of HPV persistent infection.